Gaifa Lai
8Patents
6h-index
55Co-inventors
58Inventor score
Filing activity: Jul 30, 2003 → Mar 14, 2012
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7132445B2 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | Chemistry; Metallurgy | 36 | Expired |
| US7763609B2 | Heterocyclic aspartyl protease inhibitors | Human Necessities | 34 | Active |
| US7964646B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | Chemistry; Metallurgy | 9 | Active |
| US8691831B2 | Heterocyclic aspartyl protease inhibitors | Human Necessities | 7 | Active |
| US8829036B2 | Heterocyclic aspartyl protease inhibitors | Human Necessities | 7 | Active |
| US8691833B2 | Heterocyclic aspartyl protease inhibitors | Human Necessities | 7 | Active |
| US7671212B2 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | Chemistry; Metallurgy | 3 | Active |
| US7691856B2 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.